How best is to discontinue postmenopausal hormone therapy: Immediate or tapered?

Maturitas

Volumn 56, Issue 1, 2007, Pages 78-83

  Aslan, Erdogan ^a   Bagis, Tayfun ^a   Kilicdag, Esra Bulgan ^a   Tarim, Ebru ^a   Erkanli, Serkan ^a   Kuscu, Esra ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Discontinuing; Hormone therapy; Hot flushes; Immediate; Tapering

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; NORETHISTERONE ACETATE; TIBOLONE; TRISEQUENS;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; UNIVERSITY HOSPITAL;

DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; PROSPECTIVE STUDIES; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 33845461247     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.06.006     Document Type: Article

References (18)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
2. Hulley S., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
3. Simon J.A., Hsia J., Cauley J.A., et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-Progestin Replacement Study (HERS). Circulation 103 (2001) 638-642
4. Skouby S.O., Al-Azzawi F., Barlow D., et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 51 1 (2005) 1-3
5. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)s publication. Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms, and vulvar vaginal atrophy symptoms: recommendations for clinical evaluation, 2003. Available at http://www.fda.gov/cder/guidance/5412dft.pdf (accessed on April 9, 2003).
6. Kronenberg F. Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol 29 (1994) 319-336
7. Staropoli C.A., Flaws J.A., Bush T.L., and Moulton A.W. Predictors of menopausal hot flashes. J Women's Health 7 9 (1998) 1149-1155
8. Feldman B.M., Voda A., and Gronseth E. Prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health 8 3 (1985) 261-268
9. Loprinzi C.L., Kugler J.W., Sloan J.A., et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 356 (2000) 2059-2063
10. Stearns V., Isaacs C., Rowland J., et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 11 (2000) 17-22
11. Goldberg R.M., Loprinzi C.L., O'Fallon J., et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 12 (1994) 155-158
12. Waldinger M.D., Berendsen H.H.G., and Schweitzer D.H. Treatment of hot flashes with mirtazapine: four case reports. Maturitas 36 (2000) 165-168
13. Tarim E., Bagis T., Kilicdag E., Erkanli S., Aslan E., and Kuscu E. Moclobemide in the treatment of hot flashes in postmenopausal women. Adv Ther 19 6 (2002) 258-265
14. Avis N.E., Ory M., Matthews K.A., Schocken M., Bromberger J., and Colvin A. Health related quality of life in a multicentric sample of middle aged women: Study of Women's Health Across the Nation (SWAN). Med Care 41 11 (2003) 1262-1276
15. Grady D., Ettinger B., Tosteson A., Pressman A., and Macer J. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 102 (2003) 1233-1239
16. Sloan J.A., Loprinzi C.L., Novotny P.J., Barton D.L., Lavasseur B.I., and Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 19 (2001) 4280-4290
17. Carpenter J.S., Andrykowski M.A., Freedman R.R., and Munn R. Feasibility and psychometrics of an ambulatory hot flash monitoring device. Menopause 6 (1999) 209-215
18. Carpenter J.S. The hot flash related daily interference scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manage 22 6 (2001) 979-989